Skip to main content

Table 3 Clinical characteristics of patients with SpA across Latin America

From: Prevalence, demographics, and clinical characteristics of Latin American patients with spondyloarthritis

Country Study # Patients HLA-B27 positive (%) CRP, mg/dL BASDAI BASFI ASQoL
Argentina Marengo et al., 2008 [17] 61 n/r n/r 27.2* (Em)
57.7* (Un)
40.3* (Em)
53.1* (Un)
5* (Em)
8* (Un)
Bellomio et al., 2008 [18] 405 46 1.9*b 4.0 3.3 5
Buschiazzo et al., 2011 [19] 402 45.3 n/r 3.8* 2.6* n/r
Schneeberger et al., 2015 [21] 73 5 n/r n/r n/r n/r
Sommerfleck et al., 2018 [22] 86 n/r n/r 3.3 (0 c-m)
4.3 (1–2 c-m)
5.8 (≥3 c-m)
3.2 (0 c-m)
4.5 (1–2 c-m)
5.2 (≥3 c-m)
n/r
Sommerfleck et al., 2018 [23] 50 n/r n/r 4.1* 4.2* 11.2* (PsAQoL)
Scarafia et al., 2016 (CA) [24] 92 5.6 n/r n/r n/r n/r
Brazil Sampaio-Barros et al., 2008 [26] 1036 69.5 n/r 4.1 4.5 n/r
Skare et al., 2012 [27] 1318 72.8 (W)
62.4 (AB)
35 (O)
9.3 (W)b
9.3 (AB)b
11.2 (O)b
4.0 (W)
4.3 (AB)
4.4 (O)
4.4 (W)
4.8 (AB)
4.7 (O)
7.1 (W)
8.6 (AB)
8.7 (O)
Skare et al., 2012 [28] 1424 72.8 (< 40 y)
49.5 (≥40 y)
10.3 (< 40 y)
8.02 (≥40 y)
4.15 (< 40 y)
4.47 (≥40 y)
4.6 (< 40 y)
4.7 (≥40 y)
7.8 (< 40 y)
7.8 (≥40 y)
Duarte et al., 2014 [30] 1189 67.9 n/r 4.3 4.7 7.9
Ribeiro et al., 2018 [31] 202 64.2 3.6 (W)b
3.7 (NW)b
3.6 (W)
3.7 (NW)
4.5 (W)
4.1 (NW)
7.9 (W)
6.5 (NW)
Simioni et al., 2019 [32] 85 69.2 8* 2.4* 5.1* 9.2*
Chile Gutiérrez et al., 2008 [34] 109 66.4 16.2b 4.9 4.5 n/r
Ibáñez et al., 2019 (CA) [35] 472 n/r n/r 6.1 5 10a
Colombia Bautista-Molano et al., 2016 [37] 581 43.9 11.7 5.4 (Ax)
5.3 (Pr)
n/r n/r
Santos et al., 2017 [38] 189 40.7 n/r n/r n/r n/r
Costa Rica Sáenz Castro et al., 2008 [39] 33 57.1 0.6 4.6 3.9 n/r
Mexico Casasola-Vargas et al., 2008 [40] 172 n/r 12b 4.5 4.0 n/r
Peláez-Ballestas et al., 2013 [12] 28 14.3 n/r n/r n/r n/r
Peru Chávez-Corrales et al., 2008 [41] 60 31 n/r n/r n/r n/r
Uruguay Palleiro and Spangenberg, 2008 [42] 53 approx. 50 (AS, uSpA)
14 (PsA)
6.2 mg/L 5.3 4.3 n/r
Venezuela Chacón et al., 2008 [43] 69 n/r 8.4b 4.4 3.6 n/r
Multinational García-Kutzbach et al., 2011 [44] 233 57.1 (Costa Rica)
29 (El Salvador)
4 (Guatemala)c
n/r n/r n/r n/r
Benegas et al., 2012 [45] 1083 71 10b 4.3 4.8 7
Bautista-Molano et al., 2018 [46] 390 n/r n/r n/r 3.4 n/r
  1. Continuous values are mean unless indicated (*) as median
  2. References are articles unless indicated as conference abstracts (CA)
  3. aASAS Health Index.
  4. bUnits (mg/dL or mg/L) not given in publication.
  5. cHLA-B27 test not routinely performed.
  6. AB African-Brazilian, AS ankylosing spondylitis, ASQoL Ankylosing Spondylitis Quality of Life, Ax patients with axial SpA, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, BASFI Bath Ankylosing Spondylitis Functional Index, CA conference abstract, c-m comorbidities, Em employed, HLA human leukocyte antigen, I indigenous, n/r not reported, NW non-white, MR mixed race (white-black), Pr patients with peripheral SpA, PsA psoriatic arthritis, Un unemployed, uSpA undifferentiated spondyloarthritis, W white, y years